More Clarity on Roles, Terminology Sought on IRB Draft Guidance

Devices & Diagnostics Letter
Industry and patient advocacy groups are asking the FDA to clarify roles and terminologies in its recent draft guidance on oversight of investigators and sites and IND approvability.

To View This Article:


Subscribe To Devices & Diagnostics Letter

Buy This Article Now

Add this article to your cart for $25.00